ROCHE GLYCART AG

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
C07K PEPTIDES 5779
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 29226
 
  
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 1782
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 15152
 
  
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 495
 
  
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 4202
 
  
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 148
 
  
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 1124

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2017/0260,265 BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES AND THEIR USE IN THE TREATMENT OF OCULAR VASCULAR DISEASESMay 23, 17Sep 14, 17[C07K]
2017/0198,043 BISPECIFIC ANTIGEN BINDING MOLECULESOct 20, 16Jul 13, 17[C07K]
2017/0137,530 ANTIBODY FC VARIANTSSep 07, 16May 18, 17[C07K]
2015/0274,845 BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USEMay 05, 14Oct 01, 15[C07K]
2015/0239,981 ANTIBODY FC VARIANTSJan 22, 15Aug 27, 15[C07K]
2015/0218,244 INTERLEUKIN-10 FUSION PROTEINS AND USES THEREOFFeb 04, 15Aug 06, 15[C07K]
2013/0078,249 BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULESAug 21, 12Mar 28, 13[C07K]
2013/0060,011 FC-FREE ANTIBODIES COMPRISING TWO FAB FRAGMENTS AND METHODS OF USEAug 21, 12Mar 07, 13[C12P, C12N, C07K]

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9771427 ASGPR antibodies and uses thereofAug 06, 13Sep 26, 17[A61K, C07K]
9718885 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicityJul 10, 15Aug 01, 17[C12P, C07K]
9695233 Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseasesJul 11, 13Jul 04, 17[A61K, C07K]
9650442 Bispecific anti-EGFR/anti IGF-1R antibodiesMar 20, 14May 16, 17[C07K]
9631023 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicityMar 24, 16Apr 25, 17[A61K, C12P, C12N, C07K]
9611331 Anti-HER3 antibodies and uses thereofSep 08, 14Apr 04, 17[A61K, C07K]
9526797 Combination IL-2 immunoconjugate therapyAug 07, 13Dec 27, 16[A61K, C07K]
9481730 DR5—FAP bispecific death receptor agonistic antibodiesSep 27, 10Nov 01, 16[C12N, C07K]
9447159 ImmunoconjugatesApr 26, 12Sep 20, 16[A61K, C12P, C12N, C07K]
9360481 Predictive biomarker for cancer treatment with ADCC-enhanced antibodiesJan 21, 14Jun 07, 16[A61K, G01N, C07K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2017/0174,776 METHOD AND CONSTRUCTS FOR THE pH DEPENDENT PASSAGE OF THE BLOOD-BRAIN-BARRIERAbandonedDec 01, 15Jun 22, 17[C07K]
2016/0264,651 ANTI-TENASCIN-C A2 ANTIBODIES AND METHODS OF USEAbandonedSep 02, 15Sep 15, 16[A61K, C07K]
2016/0229,923 ANTI-CEA ANTIBODIESAbandonedOct 30, 15Aug 11, 16[A61K, A61N, C07K]
2016/0166,688 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINEAbandonedMay 08, 14Jun 16, 16[A61K]
2016/0145,354 BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULESAbandonedAug 25, 15May 26, 16[C07K]
2016/0090,407 INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOFAbandonedDec 11, 15Mar 31, 16[C07K]
2016/0083,477 Removal of Cancer Cells by Circulating Virus-Specific Cytotoxic T-Cells Using Cancer Cell Targeted MHC Class 1 Compromising Multi-Function ProteinsAbandonedMay 28, 15Mar 24, 16[C12N, C07K]
2016/0075,795 Antibodies to Carcinoembryonic Antigen (CEA), Methods of Making Same, and Uses ThereofAbandonedMay 26, 15Mar 17, 16[C07K]
2016/0058,891 IN VIVO ADCC MODELAbandonedOct 29, 12Mar 03, 16[A61K, A01K, G01N]
2016/0017,050 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH AN ANTI-VEGFAbandonedSep 17, 15Jan 21, 16[A61K, C07K]
2016/0000,911 COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXITY (ADCC)AbandonedJun 05, 14Jan 07, 16[A61K]
2016/0000,912 COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITORAbandonedJun 16, 14Jan 07, 16[A61K]
2015/0344,584 Modified Antigen Binding Molecules With Altered Cell Signaling ActivityAbandonedDec 19, 14Dec 03, 15[C07K]
2015/0274,834 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONEAbandonedJun 15, 15Oct 01, 15[A61K, C07K]
2015/0265,703 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITORAbandonedJun 04, 15Sep 24, 15[A61K, A61N]
2015/0079,023 COMBINATION THERAPYAbandonedApr 16, 14Mar 19, 15[A61K, A61N]
2015/0079,073 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONEAbandonedApr 11, 14Mar 19, 15[A61K]
2015/0071,911 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITORAbandonedMar 31, 14Mar 12, 15[A61K, C07K]
2014/0377,272 ANTI-HER3 ANTIBODIES AND USES THEREOFAbandonedSep 08, 14Dec 25, 14[C07K]
2014/0322,200 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH AN ANTI-VEGF ANTIBODYAbandonedNov 27, 13Oct 30, 14[A61K, A61N]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.